FIS
CBIO

FCPM III Services’s Crescent Biopharma CBIO Stock Holding History

FCPM III Services’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.2M Hold
1,677,852
– – 4.02% 7
2026
Q1 		$30.8M Hold
1,677,852
– – 4.27% 7
2025
Q4 		$19.9M Buy
+1,677,852
New +$21.4M 2.61% 9

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

FCPM III Services's CBIO Position: Q2 2026 in Review

FCPM III Services held its Crescent Biopharma (CBIO) position steady in Q2 2026 at 1,677,852 shares worth $30.2M. The position accounts for 4.02% of the portfolio, ranked #7.

FCPM III Services first reported a position in CBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $30.8M in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • FCPM III Services held 1,677,852 shares of Crescent Biopharma worth $30.2M as of Q2 2026.
  • FCPM III Services left its Crescent Biopharma share count unchanged in Q2 2026.
  • Crescent Biopharma made up 4.02% of FCPM III Services's portfolio in Q2 2026, its #7 holding.
  • FCPM III Services first reported a position in Crescent Biopharma in Q4 2025 and has held it in 3 quarters since.
  • FCPM III Services's Crescent Biopharma position peaked at $30.8M in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on FCPM III Services's 13F filing for Q2 2026, filed 14 Aug 2026.